TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02439398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic human cardiac stem cells (CSCs)
Description: Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Human Serum Albumin-HSA 5%
Description: Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
Study: NCT01751152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
Study: NCT00202449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prazosin
Description: taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 20 mg taken at 10a for duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01946438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Description: 0.5 mL, Intramuscular
Study: NCT04138693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-PUR® 2x 2.0 g oral suspension
Description: Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-PUR® 1x 2.0 g oral suspension
Description: Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
Study: NCT00417339

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: individualised

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: individualised

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: individualised

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: individualised
Study: NCT02457559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally
Study: NCT02978417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral naltrexone
Description: Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
Study: NCT03433937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Wound dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micropore tape
Description: Wound dressing
Study: NCT00539981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBlok®
Description: Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
Study: NCT02996201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Completion of PRO-CTCAE items before consultation
Description: Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
Study: NCT01323582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: 200mg/5ml elixir administered orally three times a day half an hour prior to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
Study: NCT03402737

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: The range of dose-painting will be escalated in following levels:~* 2x 6-8Gy (day 1-4)~* 3x 6-8Gy (day 1-4-7)~* 3x 6-10Gy (day 1-4-7)~* 3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide.
Study: NCT02403557

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Weekly check up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-delivered CBT
Description: Tailored Internet-delivered CBT during 8 weeks.
Study: NCT03118310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 diet
Description: Dietary intervention according to 5:2 diet during three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCHF
Description: Dietary intervention according to LCHF diet during three months.
Study: NCT02457559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally
Study: NCT03118310

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo diet
Description: Placebo diet: normal dietary advice
Study: NCT02424773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Canula (HFNC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Study: NCT02457559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally
Study: NCT02462694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
Study: NCT00083889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alfa
Description: 3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
Study: NCT00547508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
Study: NCT00547508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
Study: NCT04368026

Intervention type: OTHER
Intervention: No intervention (survey study for medical doctors).
Description: No intervention
Study: NCT02457559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets or capsules administered orally
Study: NCT01232179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional prp
Description: pan retinal photocoagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: targeted prp
Description: 1200-1600 spot in far periphery retin, anterior equator
Study: NCT02244645

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: passive modality
Description: Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga treatment
Description: Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
Study: NCT02341859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens
Study: NCT00564681

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin type A
Description: Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
Study: NCT02341859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: contact lens
Study: NCT00564681

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin type A Formulation 2
Description: Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A Formulation 2
Description: Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
Study: NCT01334060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
Description: p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
Description: p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
Study: NCT05072639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Meditation
Description: 23 minute audio recording
Study: NCT02676414

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive hypertension education program of the DHL©
Study: NCT03998540

Intervention type: DIAGNOSTIC_TEST
Intervention: Western blot
Description: Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein

Intervention type: OTHER
Intervention: Protein interaction studies
Description: Analyses of several interacting proteins by specific Western-blot and in-vitro tests.

Intervention type: OTHER
Intervention: Mass Spectometry
Description: samples previously used for western blotting will be subjected to mass spectrometry analysis

Intervention type: OTHER
Intervention: RNA seq
Description: analyze muscle gene expression in patients with titinopathies in our cohort by RNAseq
Study: NCT02236286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
Study: NCT04771832

Intervention type: PROCEDURE
Intervention: ERAS
Description: Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
Study: NCT02066363

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietician advise
Description: Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietician advise
Description: Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Supportive parenteral nutrition.
Study: NCT01043172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
Study: NCT02021565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group
Description: Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Intervention Control Group
Description: Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
Study: NCT00468169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250mg/m2(day 1, weekly x 10);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250mg/m2(day 1, weekly x 10);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 600 mg/m2/day; days 0-5 (120 h total) every other week x 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 500 mg PO BID, days 0-5 every other week x 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Twice-daily radiation
Description: 150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m2, week 1 and 4 on day 1 (or 2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated fraction radiotherapy with concomitant boost
Description: 72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
Study: NCT03174184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral administration of rifampin at a dosage of 20 mg/kg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral administration of rifampin at a dosage of 20 mg/kg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEROPENEM 2 grams TID
Description: Intravenous administration at a dosage of 2 grams thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEROPENEM 2 grams TID
Description: Intravenous administration at a dosage of 2 grams thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEROPENEM 2 grams TID
Description: Intravenous administration at a dosage of 2 grams thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEROPENEM 2 grams TID
Description: Intravenous administration at a dosage of 2 grams thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEROPENEM 1 gram TID
Description: Intravenous administration at a dosage of 1 gram thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEROPENEM 3 grams QD
Description: Intravenous administration at a dosage of 3 grams once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
Description: Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
Description: Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
Description: Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
Description: Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
Description: Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
Description: Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
Study: NCT02023424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (Copaxone®)
Description: GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
Study: NCT04387448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFB-887
Description: Investigational Medicinal Product (IMP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching
Study: NCT02343835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife LEDC System
Description: Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.